Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 25 , ISSUE 8 ( August, 2021 ) > List of Articles

Original Article

Clinical Profile of Prosthetic Valve Endocarditis due to Candida parapsilosis: An 11-year Retrospective Observational Study from a Quaternary Cardiac Referral Institute in India

Dinoop K Ponnambath, Arun Gopalakrishnan, Vivek V Pillai, Jyothi E Kaviyil, Kavita Raja

Keywords : Candida parapsilosis, Heart valve prosthesis, Infective endocarditis, Retrospective study

Citation Information : Ponnambath DK, Gopalakrishnan A, Pillai VV, Kaviyil JE, Raja K. Clinical Profile of Prosthetic Valve Endocarditis due to Candida parapsilosis: An 11-year Retrospective Observational Study from a Quaternary Cardiac Referral Institute in India. Indian J Crit Care Med 2021; 25 (8):860-865.

DOI: 10.5005/jp-journals-10071-23915

License: CC BY-NC 4.0

Published Online: 12-08-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background: Recent changes in the diagnostic criteria and the introduction of newer technologies like prosthetic valve replacement require the need to identify the changing epidemiology of prosthetic valve endocarditis (PVE). Materials and methods: This is a retrospective, cross-sectional, observational study. Patients diagnosed with Candida parapsilosis definite and possible PVE as per modified Duke\'s criteria for a period of 11 years from January 2010 to December 2020 were included for the analysis. Results: Twelve of the 47 PVE cases (25.5%) were caused by C. parapsilosis. The median age of the patients was 52 years. Males were predominantly affected (58%). Based on the modified Duke\'s criteria, eight (67%) were definite infective endocarditis (IE) cases. The single valve was affected in 11 cases (92%) with the mitral valve being the commonest (n = 8, 67%). The type of valve commonly involved was mechanical [n = 10, 83%]. The mean size of the vegetation was 13.15 mm. Most cases (n = 7, 58%) were late-onset PVE. The mean C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) levels for C. parapsilosis PVE were 70.2 mg/L, 51.08 mm/hour, and 0.3 ng/mL, respectively. The rates of complications and in-hospital mortality were 75% each. The most common observed complication was embolic events (n = 8, 67%). Statistical significance (p ≤ 0.05) was observed for mean vegetation size, overall complications, embolic events, and mortality for C. parapsilosis PVE when compared with bacterial PVE. Conclusion: C. parapsilosis was the commonest etiological agent causing PVE. Predominant mitral valve involvement, higher rates of late-onset presentation, complications, and mortality were key differential characteristics observed.


PDF Share
  1. Siciliano RF, Randi BA, Gualandro DM, Sampaio RO, Bittencourt MS, da Silva Pelaes CE, et al. Early-onset prosthetic valve endocarditis definition revisited: Prospective study and literature review. Int J Infect Dis 2018;67:3–6. DOI: 10.1016/j.ijid.2017.09.004.
  2. Luciani N, Mossuto E, Ricci D, Luciani M, Russo M, Salsano A, et al. Prosthetic valve endocarditis: predictors of early outcome of surgical therapy. a multicentric study. Eur J Cardio-Thoracic Surg 2017;52(4):768–774. DOI: 10.1093/ejcts/ezx169.
  3. Ivanovic B, Trifunovic D, Matic S, Petrovic J, Sacic D, Tadic M. Prosthetic valve endocarditis – a trouble or a challenge? J Cardiol 2019;73(2):126–133. DOI: 10.1016/j.jjcc.2018.08.007.
  4. Østergaard L, Valeur N, Ihlemann N, Bundgaard H, Gislason G, Torp-Pedersen C, et al. Incidence of infective endocarditis among patients considered at high risk. Eur Heart J 2018;39(7):623–629. DOI: 10.1093/eurheartj/ehx682.
  5. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals From the American Heart Association. Circulation 2015;132(15):1435–1486. DOI: 10.1161/CIR.0000000000000296.
  6. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995–2000. Chest 2002;122(1):302–310. DOI: 10.1378/chest.122.1.302.
  7. Giuliano S, Guastalegname M, Russo A, Falcone M, Ravasio V, Rizzi M, et al. Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. Expert Rev Anti-infect Ther 2017;15(9):807–818. DOI: 10.1080/14787210.2017.1372749.
  8. Rivoisy C, Vena A, Schaeffer L, Charlier C, Fontanet A, Delahaye F, et al. Prosthetic valve Candida spp. endocarditis: new insights into long-term prognosis—the ESCAPE study. ClinInfect Dis 2018;66(6):825–832. DOI: 10.1093/cid/cix913.
  9. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001;32(1):50–62. DOI: 10.1086/317550.
  10. Rivas P, Alonso J, Moya J, de Górgolas M, Martinell J, Fernández Guerrero ML. The impact of hospital-acquired infections on the microbial etiology and prognosis of late-onset prosthetic valve endocarditis. Chest 2005;128(2):764–771. DOI: 10.1378/chest.128.2.764.
  11. Russo A, Falcone M, Picciarella A, Giuliano S, Raponi G, Venditti M. Candidaemia after heart valve replacement surgery: recurrence as prosthetic valve endocarditis is an expected over one-year complication. Clin Microbiol Infect 2016;22(5):466–467. DOI: 10.1016/j.cmi.2016.01.019.
  12. Giacobbe DR, Salsano A, Del Puente F, Miette A, Vena A, Corcione S, et al. Risk factors for candidemia after open heart surgery: results from a multicenter case–control study. Open Forum Infect Dis 2020;7(8):ofaa233. DOI: 10.1093/ofid/ofaa233.
  13. Evangelista A, Gonzalez-Alujas MT. Echocardiography in infective endocarditis. Heart 2004;90(6):614–617. DOI: 10.1136/hrt.2003.029868.
  14. Bruun NE, Habib G, Thuny F, Sogaard P. Cardiac imaging in infectious endocarditis. Eur Heart J 2014;35(10):624–632. DOI: 10.1093/eurheartj/eht274.
  15. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: the task force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36(44):3075–3128. DOI: 10.1093/eurheartj/ehv319.
  16. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation [Internet] 2017;135(25):e1159-e1195. DOI: 10.1161/CIR.0000000000000503.
  17. Anantha-Narayanan M, Reddy YNV, Sundaram V, Murad MH, Erwin PJ, Baddour LM, et al. Endocarditis risk with bioprosthetic and mechanical valves: systematic review and meta-analysis. Heart 2020;106(18):1413–1419. DOI: 10.1136/heartjnl-2020-316718.
  18. Nonaka M, Kusuhara T, An K, Nakatsuka D, Sekine Y, Iwakura A, et al. Comparison between early and late prosthetic valve endocarditis: clinical characteristics and outcomes. J Heart Valve Dis 2013;22(4):567–574. PMID: 24224422.
  19. Arnold CJ, Johnson M, Bayer AS, Bradley S, Giannitsioti E, Miró JM, et al. Candida infective endocarditis: an observational cohort study with a focus on therapy. Antimicrob Agents Chemother 2015;59(4):2365–2373. DOI: 10.1128/AAC.04867-14.
  20. Lefort A, Chartier L, Sendid B, Wolff M, Mainardi J-L, Podglajen I, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect 2012;18(4):E99–E109. DOI: 10.1111/j.1469-0691.2012.03764.x.
  21. Soldini S, Posteraro B, Vella A, De Carolis E, Borghi E, Falleni M, et al. Microbiologic and clinical characteristics of biofilm-forming Candida parapsilosis isolates associated with fungaemia and their impact on mortality. Clin Microbiol Infect 2018;24(7):771–777. DOI: 10.1016/j.cmi.2017.11.005.
  22. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1–e50. DOI: 10.1093/cid/civ933.
  23. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18:19–37. DOI: 10.1111/1469-0691.12039.
  24. Høiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G, et al. ESCMID* guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect 2015;21:S1–25. DOI: 10.1016/j.cmi.2014.10.024.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.